Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how biosimilar placement on formularies affects physicians' willingness to prescribe these agents.
Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health researcher who has long been an advocate for biosimilars. He has also developed guidelines in support of using biosimilars in the oncology space.
Transcript:
What’s your take on payer formularies and how biosimilar placements on these preferred lists affect use at the physician level?
Lyman: Well, the payer formularies and prioritization, in some cases, have a fairly profound impact on what drugs oncologists and other clinicians can use because it directly impacts the patient. Oftentimes, by prioritizing a certain therapy or certain biologic, a payer is saying that we will cover that and either not cover alternatives if you decide to not to use the favored agent or not pay at all. The burden is left either on the patient in terms of a much higher cost of care or is borne by the institution and the provider, which, of course, is not an attractive option either.
So, in the end, although we talk about guidelines and how health care systems themselves have their own favorite agents, ultimately, they have to meld with the payer because of that reimbursement for these costly drugs. If [a drug] is not fully reimbursed, that directly impacts the patient and the provider. So, I would say it's a fairly dramatic effect.
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.